1-9 of 9
Rolf Peter Mueller
Close
Sort by
Journal Articles

Assessment of Residual Bulky Tumor Using FDG-PET In Patients with Advanced-Stage Hodgkin Lymphoma After Completion of Chemotherapy: Final Report of the GHSG HD15 Trial

Andreas Engert, MD, Carsten Kobe, Jana Markova, Heinz Haverkamp, Peter Borchmann, Felicitas Hitz, Josee Zijlstra, Hans Eich, Rolf-Peter Mueller, Markus Dietlein, Volker Diehl
Journal: Blood
Blood (2010) 116 (21): 764.
https://doi.org/10.1182/blood.V116.21.764.764
Published: 2010
Journal Articles

Dose-Escalation with BEACOPP Escalated Is Superior to ABVD In the Combined-Modality Treatment of Early Unfavorable Hodgkin Lymphoma: Final Analysis of the German Hodgkin Study Group (GHSG) HD14 Trial

Andreas Engert, MD, Peter Borchmann, MD, Annette Pluetschow, Bastian von Tresckow, Jana Markova, Felicitas Hitz, Zdenek Kral, Richard Greil, MD, Max S Topp, Matthias Villalobos, Josee M. Zijlstra, Martin Soekler, Harald Stein, MD, Hans-Theodor Eich, Rolf-Peter Mueller, Michael Fuchs, Volker Diehl
Journal: Blood
Blood (2010) 116 (21): 765.
https://doi.org/10.1182/blood.V116.21.765.765
Published: 2010
Journal Articles

Two Cycles of ABVD Followed by Involved Field Radiotherapy with 20 Gray (Gy) Is the New Standard of Care in the Treatment of Patients with Early-Stage Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group (GHSG) HD10. Study Supported by the Deutsche Krebshilfe and in Part by the Competence Network Malignant Lymphoma.

Andreas Engert, MD, Volker Diehl, MD, Emeritus, Annette Pluetschow, Hans T. Eich, Richard Herrmann, MD, Bernd Doerken, Lothar Kanz, MD, Richard Greil, Jana Markova, Michael Fuchs, Peter Borchmann, PD, Dr., Hans Konrad Mueller-Hermelink, Rolf Peter Mueller
Journal: Blood
Blood (2009) 114 (22): 716.
https://doi.org/10.1182/blood.V114.22.716.716
Published: 2009
Journal Articles

Combined Modality Treatment with Intensified Chemotherapy and Dose-Reduced Involved Field Radiotherapy in Patients with Early Unfavourable Hodgkin Lymphoma (HL): Final Analysis of the German Hodgkin Study Group (GHSG) HD11 Trial.

Peter Borchmann, Volker Diehl, Helen Goergen, Horst Mueller, Rolf Peter Mueller, Hans T. Eich, Hans Konrad Mueller-Hermelink, Richard Herrmann, MD, Jana Markova, Anthony D. Ho, MD, PhD, Wolfgang Hiddemann, Bernd Doerken, Richard Greil, Andreas Engert, MD
Journal: Blood
Blood (2009) 114 (22): 717.
https://doi.org/10.1182/blood.V114.22.717.717
Published: 2009
Journal Articles

Hodgkin Lymphoma in Adolescents Treated with Adult Protocols: An Analysis From the German Hodgkin Study Group (GHSG).

Dennis A. Eichenauer, Henning Bredenfeld, Jeremy Franklin, Heinz Haverkamp, Horst Mueller, Hans T. Eich, Rolf-Peter Mueller, Michael Fuchs, Peter Borchmann, Volker Diehl, Andreas Engert
Journal: Blood
Blood (2009) 114 (22): 719.
https://doi.org/10.1182/blood.V114.22.719.719
Published: 2009
Journal Articles

Dose-Intensified Combined Modality Treatment with 2 Cycles of BEACOPP Escalated Followed by 2 Cycles of ABVD and Involved Field Radiotherapy (IF-RT) Is Superior to 4 Cycles of ABVD and IFRT in Patients with Early Unfavourable Hodgkin Lymphoma (HL): An Analysis of the German Hodgkin Study Group (GHSG) HD14 Trial

Peter Borchmann, Andreas Engert, Annette Pluetschow, Michael Fuchs, Jana Markova, Andreas Lohri, Zdenek Kral, Richard Greil, Max Topp, Matthias Villalobos, Jose Zijlstra, MD, Martin Soekler, Harald Stein, Hans Theodor Eich, Rolf Peter Mueller, Volker Diehl
Journal: Blood
Blood (2008) 112 (11): 367.
https://doi.org/10.1182/blood.V112.11.367.367
Published: 2008
Journal Articles

Eight Cycles of BEACOPP Escalated Compared with 4 Cycles of BEACOPP Escalated Followed by 4 Cycles of BEACOPP Baseline with Our without Radiotherapy in Patients in Advanced Stage Hodgkin Lymphoma (HL): Final Analysis of the Randomised HD12 Trial of the German Hodgkin Study Group (GHSG).

Volker Diehl, Heinz Haverkamp, Rolf Peter Mueller, Hans Theodor Eich, Hans Konrad Mueller-Hermelink, Thomas Cerny, Jana Markova, Anthony Ho, Lothar Kanz, Richard Greil, Wolfgang Hiddemann, Andreas Engert
Journal: Blood
Blood (2008) 112 (11): 1558.
https://doi.org/10.1182/blood.V112.11.1558.1558
Published: 2008
Journal Articles

Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma

Clinical Trials & Observations
Carsten Kobe, Markus Dietlein, Jeremy Franklin, Jana Markova, Andreas Lohri, Holger Amthauer, Susanne Klutmann, Wolfram H. Knapp, Josee M. Zijlstra, Andreas Bockisch, Matthias Weckesser, Reinhard Lorenz, Mathias Schreckenberger, Roland Bares, Hans T. Eich, Rolf-Peter Mueller, Michael Fuchs, Peter Borchmann, Harald Schicha, Volker Diehl, Andreas Engert
Journal: Blood
Blood (2008) 112 (10): 3989–3994.
https://doi.org/10.1182/blood-2008-06-155820
Published: 2008
Journal Articles

HD12 Randomised Trial Comparing 8 Dose-Escalated Cycles of BEACOPP with 4 Escalated and 4 Baseline Cycles in Patients with Advanced Stage Hodgkin Lymphoma (HL): An Analysis of the German Hodgkin Lymphoma Study Group (GHSG), University of Cologne, D-50924 Cologne, Germany.

Andreas Engert, Jeremy Franklin, Rolf-Peter Mueller, Hans-Theodor Eich, Axel Gossmann, Hans Konrad Mueller-Hermelink, Thomas Cerny, Jana Markova, Anthony D. Ho, Lothar Kanz, Richard Greil, Wolfgang Hiddemann, Beate Pfistner, Volker Diehl
Journal: Blood
Blood (2006) 108 (11): 99.
https://doi.org/10.1182/blood.V108.11.99.99
Published: 2006